Drug Profile
Research programme: abuse-deterrent oral hydrocodone controlled-release - Assertio Therapeutics/Shionogi
Alternative Names: AD Combination hydrocodone; AD ER hydrocodone; Hydrocodone controlled release - Assertio Therapeutics/ShionogiLatest Information Update: 08 Jan 2022
Price :
$50
*
At a glance
- Originator Egalet
- Developer Zyla Life Sciences
- Class Antitussives; Morphinans; Opioid analgesics; Opioid peptides; Small molecules
- Mechanism of Action Opioid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Pain
Highest Development Phases
- No development reported Pain
Most Recent Events
- 20 May 2020 Assertio Therapeutics has been merged with Zyla Life Sciences to form Assertio Therapeutics
- 28 Dec 2017 No recent reports of development identified for preclinical development in Pain in Japan (PO, Controlled release)
- 20 Dec 2017 Research programme: abuse-deterrent oral hydrocodone controlled-release - Egalet/Shionogi is available for licensing as of 20 Dec 2017. http://egalet.com/